|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000107821 |
Summary for KAZALD1 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000107821 | Gene symbol | KAZALD1 |
| Gene name | Kazal type serine peptidase inhibitor domain 1 | |
| HGNC | 25460 | |
| Entrez ID | 81621 | |
| Gene type | protein_coding | |
| Synonyms | KAZALD1|FKSG40|FKSG28 | |
| UniProtAcc | Q96I82 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for KAZALD1 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| KAZALD1 | 5.12e+02 | 1.10e+00 | 2.28e-01 | 4.81e+00 | 1.52e-06 | 5.27e-06 | LUAD |
| KAZALD1 | 1.87e+02 | 1.51e+00 | 5.34e-01 | 2.83e+00 | 4.71e-03 | 1.31e-02 | CHOL |
| Differentially expressed gene analysis between tumor female and normal female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| KAZALD1 | 6.62e+02 | -1.40e+00 | 3.39e-01 | -4.13e+00 | 3.63e-05 | 4.00e-04 | STAD |
| KAZALD1 | 5.75e+02 | 1.14e+00 | 4.13e-01 | 2.77e+00 | 5.62e-03 | 1.06e-02 | KICH |
| KAZALD1 | 9.44e+02 | 1.54e+00 | 1.36e-01 | 1.13e+01 | 1.13e-29 | 5.66e-29 | BRCA |
Top |
Sex-biased somatic mutation for KAZALD1 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for KAZALD1 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg26605164 | chr10:101061808 | CGI:chr10:101060731-101063117 | promoter | 4.12e-01 | 2.94e-01 | 2.05e+00 | 4.00e-02 | 4.60e-02 | 1.18e-01 |
| BRCA | cg17333042 | chr10:101062444 | CGI:chr10:101060731-101063117 | promoter,gene body | 3.41e-01 | 2.34e-01 | 2.77e+00 | 5.65e-03 | 2.14e-02 | 1.07e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| KIRC | cg26605164 | chr10:101061808 | CGI:chr10:101060731-101063117 | promoter | 6.62e-01 | 7.88e-01 | -3.92e+00 | 8.92e-05 | 1.85e-04 | -1.26e-01 |
| LUAD | cg08227353 | chr10:101061913 | CGI:chr10:101060731-101063117 | UTR,promoter,exon,gene body | 4.42e-01 | 5.42e-01 | -3.09e+00 | 1.97e-03 | 3.43e-03 | -1.00e-01 |
| LUAD | cg15302379 | chr10:101062091 | CGI:chr10:101060731-101063117 | UTR,promoter,exon,gene body | 5.55e-01 | 6.86e-01 | -4.33e+00 | 1.48e-05 | 5.77e-05 | -1.32e-01 |
| THCA | cg10342899 | chr10:101062492 | CGI:chr10:101060731-101063117 | promoter,gene body | 3.03e-01 | 4.18e-01 | -2.78e+00 | 5.36e-03 | 1.06e-02 | -1.15e-01 |
| LUSC | cg10342899 | chr10:101062492 | CGI:chr10:101060731-101063117 | promoter,gene body | 1.58e-01 | 3.96e-02 | 3.65e+00 | 2.62e-04 | 1.13e-03 | 1.18e-01 |
| BLCA | cg17333042 | chr10:101062444 | CGI:chr10:101060731-101063117 | promoter,gene body | 3.62e-01 | 4.81e-01 | -3.04e+00 | 2.38e-03 | 4.51e-03 | -1.18e-01 |
| LIHC | cg26605164 | chr10:101061808 | CGI:chr10:101060731-101063117 | promoter | 6.58e-01 | 7.77e-01 | -2.54e+00 | 1.09e-02 | 1.32e-02 | -1.20e-01 |
| LIHC | cg17333042 | chr10:101062444 | CGI:chr10:101060731-101063117 | promoter,gene body | 2.71e-01 | 4.04e-01 | -6.41e+00 | 1.50e-10 | 3.23e-09 | -1.33e-01 |
| KIRP | cg12060422 | chr10:101061927 | CGI:chr10:101060731-101063117 | UTR,promoter,exon,gene body | 7.74e-01 | 6.62e-01 | 3.36e+00 | 7.80e-04 | 1.47e-03 | 1.12e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| COAD | cg23534216 | chr10:101061795 | CGI:chr10:101060731-101063117 | promoter | 3.20e-01 | 4.27e-01 | -4.09e+00 | 4.27e-05 | 4.27e-04 | -1.08e-01 |
| LIHC | cg07638935 | chr10:101061670 | CGI:chr10:101060731-101063117 | promoter | 4.90e-01 | 6.33e-01 | -2.06e+00 | 3.96e-02 | 4.15e-02 | -1.43e-01 |
Top |
Exon skipping events with PSI in TCGA for KAZALD1 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for KAZALD1 |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for KAZALD1 |
| TFs related to KAZALD1. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| KAZALD1 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for KAZALD1 |
| RBPs related to ES in KAZALD1. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| KAZALD1 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs317430 | chr10:108189705:T:A | - | 0.266844675507585 | 4.38753289828728e-05 | GBM | Female-baised eQTL |
| rs385500 | chr10:108187799:T:C | - | 0.241361686415175 | 0.000410897676600849 | GBM | Female-baised eQTL |
| rs388072 | chr10:108188545:T:C | - | 0.241361686415175 | 0.000410897676600849 | GBM | Female-baised eQTL |
| rs369337 | chr10:108189361:C:A | - | 0.241361686415175 | 0.000410897676600849 | GBM | Female-baised eQTL |
| rs12253302 | chr10:108667002:T:G | - | 0.192964326508419 | 0.0301793282590703 | GBM | Female-baised eQTL |
| rs2225959 | chr10:107356867:G:A | - | -0.185309348273822 | 0.0367949214170549 | GBM | Female-baised eQTL |
| rs1331167 | chr10:106177803:T:C | - | -0.122890756581935 | 0.0272578475881382 | LUSC | Female-baised eQTL |
| rs1331164 | chr10:106180531:C:A | - | -0.122052662083135 | 0.0294871588808644 | LUSC | Female-baised eQTL |
| rs3830019 | chr10:98417091:C:T | - | 0.191984365726026 | 0.0480881450183246 | LUSC | Female-baised eQTL |
| rs117544819 | chr10:93240786:T:C | - | 0.144633089599918 | 0.00863225071534467 | BLCA | Female-baised eQTL |
| rs11596005 | chr10:93241205:T:C | - | 0.144633089599918 | 0.00863225071534467 | BLCA | Female-baised eQTL |
| rs10882196 | chr10:93245283:C:A | - | 0.11621433149569 | 0.0167482272036343 | BLCA | Female-baised eQTL |
| rs1927465 | chr10:93236765:C:T | - | 0.106258137436465 | 0.0272636338977956 | BLCA | Female-baised eQTL |
| rs11193420 | chr10:107431183:C:T | - | 0.0475240986539608 | 0.0136010336706248 | LUAD | Female-baised eQTL |
| rs1676789 | chr10:107471896:G:T | - | 0.0465072803160252 | 0.0137116068770365 | LUAD | Female-baised eQTL |
| rs1541264 | chr10:100673925:G:A | - | -0.0929159576421768 | 0.0339514065809456 | COAD | Female-baised eQTL |
| rs1891914 | chr10:100674291:T:A | - | -0.0929510603187448 | 0.0407713072578157 | COAD | Female-baised eQTL |
| rs4919479 | chr10:100674390:A:G | - | -0.0929510603187448 | 0.0407713072578157 | COAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs1322006 | chr10:106620768:C:G | - | 0.168025641692589 | 0.00452443341391405 | PAAD | Male-baised eQTL |
| rs111836216 | chr10:106585173:A:G | - | 0.168969359947318 | 0.018500146950834 | PAAD | Male-baised eQTL |
| rs72821135 | chr10:106585450:T:G | - | 0.168969359947318 | 0.018500146950834 | PAAD | Male-baised eQTL |
| rs11192967 | chr10:106579574:T:C | - | 0.155789234760628 | 0.0445850290731366 | PAAD | Male-baised eQTL |
| rs11195321 | chr10:110789663:G:A | - | 0.146378473019037 | 0.00822412357749351 | THCA | Male-baised eQTL |
| rs12357780 | chr10:110791451:G:A | - | 0.127227801510832 | 0.0479460003580674 | THCA | Male-baised eQTL |
| rs61065428 | chr10:110796312:C:T | - | 0.127227801510832 | 0.0479460003580674 | THCA | Male-baised eQTL |
| rs7906194 | chr10:110798478:G:A | - | 0.127227801510832 | 0.0479460003580674 | THCA | Male-baised eQTL |
| rs61417443 | chr10:110798624:G:T | - | 0.127227801510832 | 0.0479460003580674 | THCA | Male-baised eQTL |
| rs10509685 | chr10:95261632:G:A | - | 0.0564808682045482 | 0.00128022208912167 | BLCA | Male-baised eQTL |
| rs45562941 | chr10:95262400:G:A | - | 0.0551355006746822 | 0.0018211614981987 | BLCA | Male-baised eQTL |
| rs17453729 | chr10:95266773:T:G | - | 0.0541814879921174 | 0.00288326844153729 | BLCA | Male-baised eQTL |
| rs45498798 | chr10:95252616:A:G | - | 0.0547940869604498 | 0.0030286100134236 | BLCA | Male-baised eQTL |
| rs79551183 | chr10:95253772:A:G | - | 0.0547940869604498 | 0.0030286100134236 | BLCA | Male-baised eQTL |
| rs45554238 | chr10:95255868:A:C | - | 0.0547940869604498 | 0.0030286100134236 | BLCA | Male-baised eQTL |
| rs45493292 | chr10:95259521:G:A | - | 0.0547514826178271 | 0.00305678125819723 | BLCA | Male-baised eQTL |
| rs45518536 | chr10:95260462:C:T | - | 0.0547514826178271 | 0.00305678125819723 | BLCA | Male-baised eQTL |
| rs45591738 | chr10:95261970:T:C | - | 0.0547514826178271 | 0.00305678125819723 | BLCA | Male-baised eQTL |
| rs17526000 | chr10:95267329:T:C | - | 0.0538832510286531 | 0.00313871492286118 | BLCA | Male-baised eQTL |
| rs45605435 | chr10:95242574:C:G | - | 0.0502956392764135 | 0.00550632839275567 | BLCA | Male-baised eQTL |
| rs45533831 | chr10:95268603:T:C | - | 0.0509315797001757 | 0.0144901504573208 | BLCA | Male-baised eQTL |
| rs17453764 | chr10:95266994:A:T | - | 0.0449987850113831 | 0.0185991454659869 | BLCA | Male-baised eQTL |
| rs72828055 | chr10:108792917:T:C | - | 0.0773329275195109 | 0.0456528473382066 | COAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000107821 |
| CpG Site: cg13269555 | |
| Position to Gene: gene,promoter | |
| Male Effect: -0.225402801902442 | |
| Female Effect: - | |
 | Gene ID: ENSG00000107821 |
| CpG Site: cg15302379 | |
| Position to Gene: gene,exon,promoter,UTR | |
| Male Effect: -0.450033841360335 | |
| Female Effect: - | |
 | Gene ID: ENSG00000107821 |
| CpG Site: cg08227353 | |
| Position to Gene: gene,exon,promoter,UTR | |
| Male Effect: -0.243198318538214 | |
| Female Effect: - | |
 | Gene ID: ENSG00000107821 |
| CpG Site: cg23534216 | |
| Position to Gene: promoter | |
| Male Effect: - | |
| Female Effect: -0.177057392103902 |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg13269555 | chr10:101062245 | gene,promoter | -0.225402801902442 | 7.85741968978493e-15 | -0.7349867909497574 | 6.962355048113523e-18 | PAAD |
| cg15302379 | chr10:101062091 | gene,exon,promoter,UTR | -0.450033841360335 | 3.09269279095365e-11 | -0.67342137939426 | 3.024578257503264e-14 | PAAD |
| cg08227353 | chr10:101061913 | gene,exon,promoter,UTR | -0.243198318538214 | 3.5867233683358e-09 | -0.6221904302926408 | 7.99800333878009e-12 | PAAD |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg23534216 | chr10:101061795 | promoter | -0.177057392103902 | 1.84917202804606e-05 | -0.3343680650301559 | 4.46269659653788e-08 | LUAD |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of KAZALD1 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
